share_log

復星醫藥:翌日披露報表 - 股份購回

FOSUN PHARMA: NEXT DAY DISCLOSURE RETURN - SHARE BUYBACK

HKEX ·  Nov 26, 2024 04:27

Summary by Moomoo AI

2024年11月26日,復星醫藥在香港證券交易所回購了11.7萬股H股,回購價格從每股13.96港元到14.12港元不等,總額約爲1,641,884.4港元。回購的股票將作爲庫存股持有,不會被取消。回購授權於2024年6月26日獲得批准,總授權量爲55,194,050股。此次回購佔授權當日發行股票的1.1%。 由於本次回購,復星醫藥的已發行股票數量從546,011,000股減少至545,894,000股,庫存股增加至6,046,500股。根據香港證券交易所的規定,復星醫藥在回購後的30天內不得發行新股或出售庫存股,停牌期至2024年12月26日結束。
2024年11月26日,復星醫藥在香港證券交易所回購了11.7萬股H股,回購價格從每股13.96港元到14.12港元不等,總額約爲1,641,884.4港元。回購的股票將作爲庫存股持有,不會被取消。回購授權於2024年6月26日獲得批准,總授權量爲55,194,050股。此次回購佔授權當日發行股票的1.1%。 由於本次回購,復星醫藥的已發行股票數量從546,011,000股減少至545,894,000股,庫存股增加至6,046,500股。根據香港證券交易所的規定,復星醫藥在回購後的30天內不得發行新股或出售庫存股,停牌期至2024年12月26日結束。
On November 26, 2024, fosun pharma repurchased 117,000 H shares on the Hong Kong Stock Exchange, at a repurchase price ranging from HKD 13.96 to HKD 14.12 per share, totaling approximately HKD 1,641,884.4. The repurchased shares will be held as treasury shares and not cancelled. The repurchase authorization was approved on June 26, 2024, with a total authorization of 55,194,050 shares. This repurchase accounted for 1.1% of the shares issued on the day of authorization. Due to this repurchase, the number of issued shares of fosun pharma decreased from 546,011,000 shares to 545,894,000 shares, with treasury shares increasing to 6,046,500 shares. According to the regulations of the Hong Kong Stock Exchange, fosun pharma shall not issue new shares or sell treasury shares within 30 days after the repurchase, with the suspension period ending on December 26, 2024.
On November 26, 2024, fosun pharma repurchased 117,000 H shares on the Hong Kong Stock Exchange, at a repurchase price ranging from HKD 13.96 to HKD 14.12 per share, totaling approximately HKD 1,641,884.4. The repurchased shares will be held as treasury shares and not cancelled. The repurchase authorization was approved on June 26, 2024, with a total authorization of 55,194,050 shares. This repurchase accounted for 1.1% of the shares issued on the day of authorization. Due to this repurchase, the number of issued shares of fosun pharma decreased from 546,011,000 shares to 545,894,000 shares, with treasury shares increasing to 6,046,500 shares. According to the regulations of the Hong Kong Stock Exchange, fosun pharma shall not issue new shares or sell treasury shares within 30 days after the repurchase, with the suspension period ending on December 26, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more